SmallCapReview.com has been a leading site for information on small cap stocks and penny stocks since 1999, to receive the free SmallCapReview newsletter visit http://www.smallcapreview.com.
Sanmina-SCI Corporation (Nasdaq: SANM) was introduced to subscribers of the SmallCapReview newsletter in November of 2009 at $6.63.
Sanmina-SCI Corporation (Nasdaq: SANM) $12.30. Announced Tuesday after market close financial results for the first fiscal quarter ended January 2, 2010. Revenue for the first quarter was $1.48 billion, up 9 percent compared to $1.35 billion in the prior quarter ended October 3, 2009 and up 4 percent compared to $1.42 billion in the same period a year ago.
GAAP net income in the first quarter was $59 million, a diluted earnings per share of $0.74, compared to a net loss of $33 million, a diluted loss per share of $0.42 in the prior quarter. GAAP net loss for the same period a year ago was $26 million, a diluted loss per share of $0.29. GAAP net income in the first quarter 2010 included a one-time benefit of approximately $36 million in connection with certain legal proceedings.
What They Do: Sanmina-SCI Corporation is a leading electronics contract manufacturer serving the fastest-growing segments of the global Electronics Manufacturing Services (EMS) market.
To read more about Sanmina-SCI Corporation visit http://www.smallcapreview.com/sanm.htm.
Scientific Games Corporation (Nasdaq: SGMS) $14.59, Today announced that it has entered into a definitive agreement to sell its Racing and Venue Management businesses ("Scientific Games Racing") to U.K.-based Sportech Plc (LSE: SPO), in a transaction valued at approximately $75 million. The transaction, which follows a review of strategic alternatives with respect to Scientific Games Racing, marks a significant step in the Company's strategy to focus its business portfolio and drive sustainable, profitable growth. Importantly, the transaction will enable Scientific Games to participate in future growth of the combined businesses of Sportech and Scientific Games Racing through an equity interest in Sportech that Scientific Games will receive as part of the transaction consideration. Upon the closing of the transaction, the companies intend to enter into a number of ancillary agreements to deliver additional strategic value as part of an ongoing relationship.
What They Do: Scientific Games Corporation is a leading integrated supplier of instant tickets, systems and services to lotteries worldwide, a leading supplier of server based gaming machines and systems, Amusement and Skill with Prize betting terminals, interactive sports betting terminals and systems, and wagering systems and services to pari-mutuel operators.
Cytokinetics, Incorporated (Nasdaq: CYTK) $2.96. Today announced results from its Phase I, randomized, double-blind, placebo-controlled, multiple-dose clinical trial of oral CK-2017357. The primary objective of this clinical trial was to determine the safety and tolerability of CK-2017357 after multiple oral doses to steady state in healthy male volunteers. The secondary objective was to evaluate the pharmacokinetic profile of CK-2017357 after multiple oral doses to steady state.
In this Phase I clinical trial, two cohorts, each comprised of 12 healthy males, were randomized 2:1 to receive daily morning doses of oral CK-2017357 versus matching placebo for seven days. The CK-2017357 dose was 250 mg in Cohort 1 and 375 mg in Cohort 2. At steady state, which was achieved at both dose levels by the sixth day of treatment, both the maximum CK-2017357 plasma concentration (Cmax) and the area under the CK-2017357 plasma concentration versus time curve from dosing until 24 hours after dosing (AUC24h) were generally dose proportional and exhibited only modest accumulation compared to the values measured after the first dose. In general, systemic exposure to CK-2017357 in this trial was high and inter-subject variability was low. In addition, these multiple dose regimens of CK-2017357 were well tolerated, and there were no serious adverse events.
What They Do: Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.
SunOpta Inc. (Nasdaq: STKL) $3.06. Today announced that it has commenced an environmentally responsible energy recovery project at its Cambridge, Minnesota oat fiber facility. The planned installation will extract methane from the digestion of waste-water resulting from the oat fiber production process, converting the methane to pipeline quality natural gas and using this energy to power the facility. When completed, the project will significantly reduce the release of greenhouse gases and various waste materials from the facility as well as provide an excellent return on invested capital of approximately $1 million USD. This initiative is consistent with SunOpta's stated objective of reducing its environmental footprint and promoting sustainable business practices.
SunOpta's environmental initiatives are widespread and over the past year SunOpta received two awards in recognition of the Company's commitment to environmental sustainability.
What They Do: SunOpta Inc. is an operator of high-growth ethical businesses, focusing on integrated business models in the natural and organic foods and natural health products markets.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com/. To follow us on Twitter visit http://twitter.com/SmallCapReview.
